Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
|Articles|June 1, 2002
- Pharmaceutical Technology-06-02-2002
- Volume 26
- Issue 6
Building on Tradition: Integrating the Links of Expertise
Author(s)Ronelle Russell
A profile about how a provider with a solid reputation in niche areas of contract manufacturing became a full-service operation.
Advertisement
Articles in this issue
over 24 years ago
Excipient GMP Quality Standards: One is Enoughover 24 years ago
The IPEC-Americas Excipient Master File Guideover 24 years ago
Technology Advances Anticounterfeiting Optionsover 24 years ago
Calibration of Lyophilization Pressure Gaugesover 24 years ago
Drug Shortages Reveal GMP Concernsover 24 years ago
Outsourcing Outlookover 24 years ago
Optimizing Cross-Organizational Team Performance and Managementover 24 years ago
Screening for Counterfeit Drugs Using Near-Infrared SpectroscopyAdvertisement
Related to this article
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement